Navigation Links
Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury
Date:12/16/2008

DURHAM, N.C., Dec. 16 /PRNewswire/ -- Parion Sciences, Inc., a privately-held, development-stage pharmaceutical company dedicated to treating diseases resulting from the failure of the body's mucosal defenses, today announced that the National Institutes of Health (NIH) have awarded the company a biodefense grant in excess of $850,000.

The purpose of the grant is to advance the development of safe and effective medical treatments that mitigate pulmonary injury arising from inhalation of radioactive particles using Parion's Radiation and Bioterrorism Countermeasures Platform. Parion will utilize the funding in a series of studies to evaluate the benefits of their lead compound, CF-552, combined with hypertonic saline, to increase removal of inhaled radioactive particles from the lungs. In previous clinical studies, treatment with CF-552 increased clearance of non-hazardous, radio-labeled particles from the lungs of healthy volunteers, as compared to vehicle alone. A portion of the research will be conducted by the Lovelace Respiratory Research Institute (LRRI), a not-for-profit research institute located in Albuquerque, New Mexico.

"This award represents an important step to help us demonstrate the capacity of our novel ENaC inhibitor technology to treat radiation and bio-terror threats," said Paul Boucher, Senior Director, Finance and Business at Parion. "We look forward to demonstrating the utility of our compound to provide a novel medical countermeasure for the prevention of radiation-induced lung injury following a nuclear incident."

ENaC inhibitors are therapeutic agents that maintain and stimulate hydration on the body's mucosal surfaces, including those on the lung, mouth, nose, eye and gastrointestinal tract. Maintaining the hydration of mucosal airway surfaces addresses the fundamental problem that produces infections in both acquired and genetic forms of chronic lung disease, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

The studies will be supported by Grant Number RC1-AI-081297, funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA). The award was made using authorities granted to the NIH by the Project BioShield Act of 2004. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID, BARDA, or the NIH.

About Parion Sciences

Based in Durham, NC, Parion Sciences is a privately-held, development-stage pharmaceutical company that is leveraging its proprietary small molecule chemistry and epithelial biology expertise to discover and develop an innovative pipeline of therapies for diseases resulting from the failure of the body's mucosal defenses, including chronic obstructive pulmonary disorder (COPD), cystic fibrosis, bronchiactesis and Sjogren's syndrome. Parion's lead product candidate, CF-552, is currently in Phase II clinical development for the treatment dry mouth associated with Sjogren's syndrome. The company is also collaborating with Gilead Sciences on the development of drug candidates for pulmonary diseases. For more information, please visit www.parion.com.

About Lovelace Respiratory Research Institute

Lovelace Respiratory Research Institute is a not-for-profit research institution founded in 1947 by Dr. William Randolph Lovelace II. It is one of the nation's largest independent research institutions and the only one focused solely on respiratory health. Scientists at LRRI are committed to eradicating respiratory diseases through research aimed at understanding their causes and biological mechanisms, eliminating exposures to causal agents, and developing more effective treatments. For more information see www.lrri.org.


'/>"/>
SOURCE Parion Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
2. Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment
3. Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement
4. Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
5. Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
6. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
7. YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE
8. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
9. Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia
10. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
11. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
Breaking Biology Technology:
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):